Lipocine Inc. business relationships
Companies named in Lipocine Inc.’s 10-K filed 2026-03-10, and public companies whose annual reports name Lipocine Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Layers: GLP-1 & obesity
Named in Lipocine Inc.’s annual report 2
“All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1 % royalty” SEC filing
“generic version of Axiron in the United States, through a marketing and distribution agreement between Lilly and Company and a leading” SEC filing
Companies whose annual reports name Lipocine Inc. 1
“In September 2023, we provided Lipocine notice of termination of the TLANDO license agreement effective January 31, 2024.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.